Trovagene Announces Broadening Network of Commercial Distributors
January 12, 2017 at 08:00 am
Share
Trovagene, Inc. announced that it has signed agreements with seven strategic partners across Europe and the Middle East for commercialization of the Trovera™ liquid biopsy tests. This milestone marks the first wave of international distribution agreements for Trovagene's CLIA based liquid biopsy tests for urine and blood samples. The initial partners will introduce Trovagene's liquid biopsy tests to physicians, laboratories and cancer centers in key regional markets. In addition, these partners will have early access to Trovagene's research use only liquid biopsy kits and systems to distribute to clinical research facilities in Europe, Middle East, Africa and Asia. These strategic partners include Alliance Global (AGBL) for the Middle East, Africa, Central and South Asia, Instituto Diagnostico Varelli (Italy), Progenetics (Israel), Amplitech (France, Belgium and Switzerland), NM Genomix (Bulgaria and East Europe), Diagnostica Longwood (Spain and Portugal), and Sorgente Genetica (Italy).
Cardiff Oncology, Inc. is a clinical-stage biotechnology company. It is leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the unmet medical need. It is focused on clinical programs in indications, such as RAS-mutated metastatic colorectal cancer (mCRC), and in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), and triple negative breast cancer (TNBC). Its lead drug candidate, Onvansertib, is an oral, small molecule drug candidate that is highly specific for PLK1 inhibition with a 24-hour half-life. It has five ongoing and planned clinical trials of onvansertib: one trial (CRDF-004) in first-line treatment in patients with RAS-mutated mCRC, one trial (CRDF-001) in second-line treatment in patients with mPDAC, and three investigator-initiated trials in first line mPDAC, relapsed SCLC and unresectable locally advanced or metastatic TNBC.
CARDIFF ONCOLOGY, INC. 
